• The funding will be dedicated to developing our broad-spectrum pan-flavi antiviral drug PTL244 to clinical phase II stage for the most common flavivirus: dengue.
• Dengue is endemic in more than 100 countries (a.o.
Venture Challenge alumnus Cyclomics has completed a financing round driven by a group of private investors too accelerate the development of innovate technologies in the field of cancer genetic testing.
Today the special Proefdiervrij (animal-free) edition of the Venture Challenge has started. In this Venture Challenge four teams participate with innovations that have the potential to reduce or replace animal testing.